1 / 13

Presente r Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference

Presente r Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference. Why A New Approach to Breast Cancer Screening?. Of women age 40 and over with insurance coverage only 50% participate in yearly screenings. Why women don’t participate: Dense Breast T issue

johnda
Download Presentation

Presente r Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presenter Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference

  2. Why A New Approach to Breast Cancer Screening? • Of women age 40 and over with insurance coverage only 50% participate in yearly screenings. • Why women don’t participate: • Dense Breast Tissue • Lack of Facility Access • Some find procedure painful • Cost prohibitive for uninsured • False Positive rate of 5% per exam= 50% over per patient lifetime

  3. Ascendant Diagnostics is Developing: • A Low Cost • Non-Invasive • Screening Method for Breast Cancer • Detects proteins present in tear samples • Based on technology licensed from UAMS An inexpensive, highly accurate test that can diagnose cancer at earlier stages is highly sought after

  4. Why Tears? • Easy and Quick to Collect • Pain Free • Non-invasive • Contain Protein in High Concentrations • Easy to Prep for Test Analyze Tears by Mass Spectrometry Look for Differences Collect Tear Sample

  5. Mass Spectrometry Separates samples based on Size Intensity Bigger peak=more protein Increasing size • Private Industry • Quest • LabCorp • PeaceHealth Labs Drug Testing Monitoring Pain Medication Monitor metabolic disorders

  6. Genomics vs. Proteomics ProteinStructure and Function DNA Sequences Predictive of Risk Not Diagnostic Diagnostic

  7. Imaging is the Gold Standard Tear Testing 80% Sensitive 75% Specific 90% Sensitive 90% Specific $75.00 per test vs. $200 for mammogram

  8. Regulatory Pathway CLIA: Clinical Laboratory Improvements Amendment

  9. Timeline Protein Biomarker Identification; 2 cohorts of 300 patients; establish more partnerships; develop CLIA protocol Licensed Technology;Business Case; Established Strategic Partnerships Clinical Validation; Marketing and Sales Team Build up Contract Development of POC Lab on a Chip and Contract Development of Reagents; Sales and Mktg. Other Cancer biomarkers; lines between treatment and level of protein 2011 2012 2013 2015 2014

  10. Collaborations • University of Arkansas Statewide Mass Spectrometry Facility • established February 2011 • Acess to mass spectrometry instrumentation • Collabroations on Grant applications • Aid in development of CLIA based protocol • The Breast Center • established February 2012 • 300 tear samples over the next 2 years • Peace Health Labs • Established August 2011 • Aid and in development and testing of CLIA lab protocol • Winthrop P. Rockefeller Cancer Institute Women’s clinic (UAMS) • In Progress • 300 tear samples over the next 2 years

  11. Management Team

  12. Scientific Advisory Board

  13. Contact Information • OmidMoghadam CEO 479-571-2592 omid.moghadam@ascendant-diagnostics.com • Anna Daily Ph.D. Scientist 479-571-2592 anna.daily@ascendant-diagnostics.com

More Related